JP5735724B2 - 腹腔内投与される脂質ベースの白金化合物製剤を用いた、癌の治療方法 - Google Patents

腹腔内投与される脂質ベースの白金化合物製剤を用いた、癌の治療方法 Download PDF

Info

Publication number
JP5735724B2
JP5735724B2 JP2007540183A JP2007540183A JP5735724B2 JP 5735724 B2 JP5735724 B2 JP 5735724B2 JP 2007540183 A JP2007540183 A JP 2007540183A JP 2007540183 A JP2007540183 A JP 2007540183A JP 5735724 B2 JP5735724 B2 JP 5735724B2
Authority
JP
Japan
Prior art keywords
cisplatin
lipid
platinum
use according
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2007540183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008519064A (ja
JP2008519064A5 (enExample
Inventor
フランク， ジー． ピルキービッチ，
フランク， ジー． ピルキービッチ，
ローマン ペレス−ソーラー，
ローマン ペレス−ソーラー，
イーイェ ゾー，
イーイェ ゾー，
Original Assignee
インスメッド， インコーポレイテッド
インスメッド， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インスメッド， インコーポレイテッド, インスメッド， インコーポレイテッド filed Critical インスメッド， インコーポレイテッド
Publication of JP2008519064A publication Critical patent/JP2008519064A/ja
Publication of JP2008519064A5 publication Critical patent/JP2008519064A5/ja
Application granted granted Critical
Publication of JP5735724B2 publication Critical patent/JP5735724B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2007540183A 2004-11-08 2005-11-08 腹腔内投与される脂質ベースの白金化合物製剤を用いた、癌の治療方法 Expired - Lifetime JP5735724B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62602904P 2004-11-08 2004-11-08
US60/626,029 2004-11-08
US67159305P 2005-04-15 2005-04-15
US60/671,593 2005-04-15
PCT/US2005/040489 WO2006055352A2 (en) 2004-11-08 2005-11-08 Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015040908A Division JP2015098498A (ja) 2004-11-08 2015-03-03 腹腔内投与される脂質ベースの白金化合物製剤を用いた、癌の治療方法

Publications (3)

Publication Number Publication Date
JP2008519064A JP2008519064A (ja) 2008-06-05
JP2008519064A5 JP2008519064A5 (enExample) 2013-04-11
JP5735724B2 true JP5735724B2 (ja) 2015-06-17

Family

ID=36407625

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007540183A Expired - Lifetime JP5735724B2 (ja) 2004-11-08 2005-11-08 腹腔内投与される脂質ベースの白金化合物製剤を用いた、癌の治療方法
JP2015040908A Pending JP2015098498A (ja) 2004-11-08 2015-03-03 腹腔内投与される脂質ベースの白金化合物製剤を用いた、癌の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015040908A Pending JP2015098498A (ja) 2004-11-08 2015-03-03 腹腔内投与される脂質ベースの白金化合物製剤を用いた、癌の治療方法

Country Status (9)

Country Link
US (1) US20060246124A1 (enExample)
EP (1) EP1811963A4 (enExample)
JP (2) JP5735724B2 (enExample)
KR (1) KR20070089693A (enExample)
AU (1) AU2005306802A1 (enExample)
CA (1) CA2584673A1 (enExample)
IL (1) IL182507A0 (enExample)
MX (1) MX2007004955A (enExample)
WO (1) WO2006055352A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ296459B6 (cs) * 2004-09-14 2006-03-15 Pliva-Lachema A. S. Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US7875288B2 (en) * 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
US7875289B2 (en) * 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
CZ300424B6 (cs) * 2006-06-20 2009-05-13 Pliva - Lachema A. S. Farmaceutická kompozice pro perorální podání
CZ300590B6 (cs) * 2006-06-20 2009-06-24 Pliva - Lachema A. S. Farmaceutická kompozice pro injekcní podání
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US9814672B2 (en) * 2007-03-09 2017-11-14 Susan T. Laing Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi
KR101085203B1 (ko) 2011-04-01 2011-11-21 서울대학교산학협력단 의약 전달용 인지질 나노입자
WO2014039533A2 (en) 2012-09-04 2014-03-13 Eleison Pharmaceuticals, Llc Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
CN113453667A (zh) * 2018-11-02 2021-09-28 利帕克肿瘤学有限责任公司 脂质体增强腹腔内化学疗法
MX2024009679A (es) * 2022-02-07 2024-08-15 Livful Inc Preparacion de nuevos derivados de alcoholes triterpenicos con biodisponibilidad mejorada para el tratamiento de cancer, inflamacion y dolor.
CN118059258B (zh) * 2024-03-07 2024-11-15 内蒙古工业大学 一种治疗口腔鳞状细胞癌顺铂耐药的纳米药物及其制备方法和应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451447A (en) * 1980-03-31 1984-05-29 Bristol-Myers Company Pharmaceutical formulations
US4981692A (en) * 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
USRE33071E (en) * 1983-03-28 1989-09-26 Platinum bound to transferrin for use in the treatment of breast tumors
US4590001A (en) * 1983-03-28 1986-05-20 Stjernholm Rune L Platinum bound to transferrin for use in the treatment of breast tumors
US5019369A (en) * 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
JPH0665648B2 (ja) * 1985-09-25 1994-08-24 塩野義製薬株式会社 白金系抗癌物質の安定な凍結真空乾燥製剤
US5117022A (en) * 1985-10-18 1992-05-26 The Board Of Regents, The University Of Texas System Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5041581A (en) * 1985-10-18 1991-08-20 The University Of Texas System Board Of Regents Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5320906A (en) * 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
US5616334A (en) * 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
IL83380A (en) * 1987-07-30 1991-04-15 Teva Pharma Stable aqueous cisplatin solutions
CA1335348C (en) * 1988-03-04 1995-04-25 Yasuaki Ogawa Liposome composition
US5141751A (en) * 1988-06-29 1992-08-25 Daiichi Pharmaceutical Co., Ltd. Lipid membrane structures
US5549910A (en) * 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5756353A (en) * 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5958449A (en) * 1992-12-02 1999-09-28 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for bacterial infections
US5665383A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5780054A (en) * 1996-01-17 1998-07-14 University Of British Columbia Methods for increasing the circulation half-life of protein-based therapeutics
US20010006648A1 (en) * 1996-02-26 2001-07-05 Hitoshi Yamauchi Liposomes and liposomal dispersion
DE69722793T2 (de) * 1996-04-26 2004-05-19 Genaera Corp. Squalamin in kombination mit anderen antikrebs-mittelen zur behandlung von tumoren
EP0929293B1 (en) * 1996-08-23 2003-10-22 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
US5997899A (en) * 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
US6451784B1 (en) * 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
NZ336381A (en) * 1996-12-30 2000-11-24 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6630168B1 (en) * 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
US6090407A (en) * 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
CA2248592A1 (en) * 1998-08-31 2000-02-29 Christopher D. Batich Microspheres for use in the treatment of cancer
ES2156506B1 (es) * 1998-10-14 2002-03-01 Sumitomo Chemical Co Metodo para la produccion de oxido de propileno.
US20050074499A1 (en) * 1999-03-17 2005-04-07 Mitsubishi Chemical Corporation Ligand-bonded complex
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6852334B1 (en) * 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
JP2003503313A (ja) * 1999-06-03 2003-01-28 ジェシー エル エス オウ 細胞増殖及び細胞死を変調する方法及び組成物
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6800437B1 (en) * 1999-08-06 2004-10-05 Tibotec Bvba Method of monitoring a biological system by labeling with an apo metal binding protein
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
AU777338B2 (en) * 1999-12-04 2004-10-14 Research Development Foundation Carbon dioxide enhancement of inhalation therapy
WO2001056548A2 (en) * 2000-02-04 2001-08-09 Lipoxen Technologies Limited Liposomes composition produced by a dehydration-rehydration process
US20030124180A1 (en) * 2000-05-02 2003-07-03 Jurgen Ebert Liposomes containing active substances
CN1245977C (zh) * 2000-06-30 2006-03-22 英耐克斯药品股份有限公司 脂质体抗肿瘤药物及其使用
WO2002060412A2 (en) * 2001-02-01 2002-08-08 Board Of Regents Stabilised polymeric aerosols for pulmonary gene delivery
US6723350B2 (en) * 2001-04-23 2004-04-20 Nucryst Pharmaceuticals Corp. Lubricious coatings for substrates
DK1320355T3 (da) * 2001-05-18 2006-07-31 Chiron Corp System til administration af en tobramycinformulering
AU2002323151A1 (en) * 2001-08-13 2003-03-03 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
WO2003015707A2 (en) * 2001-08-20 2003-02-27 Transave, Inc. Method for treating lung cancers
WO2003015521A1 (en) * 2001-08-20 2003-02-27 Transave, Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
JP3415131B1 (ja) * 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
AU2003302314A1 (en) * 2002-08-02 2004-07-09 Transave, Inc. Platinum aggregates and process for producing the same
US20040170677A1 (en) * 2002-11-26 2004-09-02 Ning Hu Method of drug loading in liposomes by gradient

Also Published As

Publication number Publication date
MX2007004955A (es) 2007-06-14
US20060246124A1 (en) 2006-11-02
CA2584673A1 (en) 2006-05-26
JP2008519064A (ja) 2008-06-05
KR20070089693A (ko) 2007-08-31
WO2006055352A2 (en) 2006-05-26
AU2005306802A1 (en) 2006-05-26
EP1811963A4 (en) 2010-01-06
IL182507A0 (en) 2007-09-20
WO2006055352A3 (en) 2006-07-27
EP1811963A2 (en) 2007-08-01
JP2015098498A (ja) 2015-05-28

Similar Documents

Publication Publication Date Title
JP2015098498A (ja) 腹腔内投与される脂質ベースの白金化合物製剤を用いた、癌の治療方法
CN100377704C (zh) 脂质体制剂
US20070190182A1 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
JP2006502233A (ja) 白金凝集物およびその製造方法
US9302003B2 (en) Compositions comprising a radiosensitizer and an anti-cancer agent and methods of uses thereof
US20070190181A1 (en) Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously
US20070190180A1 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
AU2005284909B2 (en) Delivering iron to an animal
US20160166608A1 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20090130194A1 (en) Methods of Treating Cancer with High Potency Lipid-Based Platinum Compound Formulations Administered Intravenously
CN101056620A (zh) 腹膜内给予以脂质为基质的铂化合物制剂治疗癌症的方法
HK1112181A (en) Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
US20080026045A1 (en) Combination Chemotherapy Comprising a Gemcitabine and a Liposomal Platium Complex
EP1631301A1 (en) Combination chemotherapy comprising 5-fluorouracil or a derivative thereof and a liposomal platinum complex

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120312

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120327

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120406

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120912

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130218

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130404

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20130501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130502

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130528

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20130621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140425

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140528

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140620

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140703

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20140703

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20141010

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20141022

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150417

R150 Certificate of patent or registration of utility model

Ref document number: 5735724

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250